Morgan Stanley is navigating a minor post-earnings pullback while peers absorb significantly heavier losses — a divergence that reinforces the relative strength story that has defined the stock's 2026.
The week's most telling signal is not in the short book, which remains negligible, but in the options market and how the stock is behaving against its peer group. MS fell 1.6% on Tuesday and 1.2% across the week to close near $189.58. That is a softer patch — but GS dropped 1.8% on the week, EVR fell 5.2%, CG slid 9.0%, and BLK lost 5.1%. Against that backdrop, MS's modest pullback looks less like weakness and more like outperformance.
Options traders have nudged more defensive following last Wednesday's earnings print. The put/call ratio climbed to 1.45, running above its 20-day average of 1.42 with a z-score of 1.38. That is a mild elevation — not a panic signal, but a continuation of the cautious tilt that was present going into the May 14 release. The 52-week PCR range runs from 1.10 to 1.62, so the current reading is in the upper half but well clear of the extreme. Earnings delivered a modest disappointment on the day — the stock fell 0.68% on May 14 — compared to the prior print, which gained 2.2% on the day and 4.2% over the following week. Borrow conditions remain entirely loose: the lending market is flush, with availability far exceeding any meaningful constraint on new short-selling. Cost to borrow has ticked up 37% on the week to 0.46% annualised, but that is still a deeply cheap, commodity-grade borrow — the absolute level signals no short-side conviction.
Short interest confirms the same absence of conviction. After the sharp compression documented over the past three weeks — SI % FF fell from roughly 1.5% in early April to a multi-month low — it has stabilised at just 0.86% of free float. That is a fraction of what would qualify as a primary short-selling story. The month-on-month decline is still running at 17%, but the pace is slowing as positions bottom out. The ORTEX short score of 29.6 sits in the 73rd percentile of the universe for rank, an apparent paradox explained by how tame the absolute short interest is: the score is low (bearish pressure absent), even as the relative rank reflects a benign setup compared to more heavily shorted names.
The Street's view is mixed but tilted constructive. Analysts at Goldman Sachs hold Neutral with a $205 target, BofA maintains Buy at $225, and Barclays carries Overweight at $230. Wells Fargo sits at Equal-Weight with a $200 target, essentially in line with the current price. The mean analyst target of $203 implies roughly 7% upside from $189.58 — modest headroom but positive. The most recent action, from Citigroup on May 8, raised the target from $170 to $194 while keeping Neutral — a concession that fair value is higher, but a vote that the easy move has been made. Valuation multiples reflect a stock that has re-rated: the P/E has eased slightly to 15.6x over the past week and month, while the P/B of 2.66x has drifted modestly lower. The EPS surprise factor score of 76 and a dividend score ranking at the 98th percentile provide fundamental support, though forward EPS growth expectations remain muted at the 24th percentile.
One notable data point from April warrants mention without over-reading. Several senior executives — both Co-Presidents and the Chief Legal Officer — sold shares between April 16 and April 20, with Co-President Andrew Saperstein's transactions alone totalling roughly $9.4 million. The sales were spread across multiple tranches and are typical of planned disposal windows that often follow earnings. The insider net 90-day figure is actually positive at $39 million, suggesting the overall insider picture over the quarter is not net-negative. All significance scores on the recent trades are low at 3/10. The headline looks busy; the signal is minimal.
The next scheduled earnings date is July 15. Between now and then, the primary variable is how much of the pipeline story — particularly the reported SpaceX IPO mandate — translates into visible fee revenue, and whether the broader financial sector selloff in peers deepens in a way that eventually pulls MS along with it or continues to spare it.
See the live data behind this article on ORTEX.
Open MS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
